-
Experts review current recommendations for management of diabetic neuropathies
During a Virtual 80th Scientific Sessions symposium, Karen L. Jones, PhD, DipAppSc, and two other experts provided an update on the latest research and current recommendations for treating diabetic neuropathies, including the clinical management of gastrointestinal autonomic neuropathies, the impact of diet and lifestyle interventions on diabetic neuropathies, and the pharmacological management of painful neuropathy.
-
SGLT2 inhibitors reduce cardiorenal disease with benefits to multiple systems
During a Scientific Sessions virtual presentation, a panel of experts, including Subodh Verma, MD, PhD, FRCSC, and Ele Ferrannini, MD, reviewed the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in metabolic mediation, in the heart, and in the kidney. SGLT2 inhibitors have a profound renal effect, they lower blood glucose levels, and they work to…
-
Researchers debate whether artificial pancreas systems should be single or dual hormone
Two researchers went head-to-head in a virtual debate examining whether artificial pancreas systems should be single hormone (insulin only) or dual hormone (insulin and glucagon or dasiglucagon) during the Scientific Sessions. Roman Hovorka, PhD, FMedSci, made the case for a single-hormone artificial pancreas system while Steven J. Russell, MD, PhD, presented a counterargument in favor…
-
Diabetes providers should screen for female sexual dysfunction, experts say
Alice Cheng, MD, FRCPC, and Sharon Parish, MD, discussed female sexual dysfunction in diabetes patients during the Virtual 80th Scientific Sessions. The majority of women with diabetes face issues related to sexual health and would like their doctors to initiate conversations about sexual dysfunction, Dr. Cheng said.
-
Erectile dysfunction common among diabetes patients, but many treatment options exist
At any time, up to half of men with diabetes may be experiencing erectile dysfunction (ED), according to Aruna V. Sarma, PhD, MHA. Dr. Sarma and Deepak K. Jumani, MBBS, FCGP, discussed ED and male sexual dysfunction in diabetes patients during a Scientific Sessions mini-symposium.
-
Combination of diabetes and heart failure presents dual challenge for endocrinologists, cardiologists
During the Scientific Sessions, an expert panel of cardiologists and endocrinologists provided an update on heart failure for diabetologists. Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, reported that 50% to 80% of people with diabetes die of cardiovascular disease.
-
Researchers looking for ways to reverse beta-cell failure and create pathway to ‘disease-modifying interventions’ for type 2 diabetes
During a Virtual 80th Scientific Sessions presentation, Domenico Accili, MD, delivered “a message of hope” for the future of type 2 diabetes treatment. “From what we’ve learned, we think that we can reverse beta-cell failure in a mechanistic manner. This should lead to truly disease-modifying interventions for patients with type 2 diabetes,” he said.
-
Benefits of CGM amplified amid COVID-19 pandemic; potential in pediatric settings studied
The coronavirus pandemic and the high number of COVID-19 patients with diabetes have heightened interest in real-time continuous glucose monitoring (CGM). “The ability to have remote access to data and time-in-range data when we’re doing telehealth consultations during the COVID pandemic has been fabulous. We may not be going back to face-to-face as often as…
-
Definition of hypoglycemia impacts clinical trial design, results
Hypoglycemia is a major barrier to achieving glucose targets that prevent diabetes complications, but there’s no consensus whether 54 mg/dL or 70 mg/dL is the best standard for hypoglycemia in clinical trials. Simon R. Heller MD, FRCP, and Aaron J. Kowalski, PhD, examined the value of the two standards during a Scientific Sessions symposium.
-
VERTIS-CV trial results support use of SGLT2 inhibitors in type 2 diabetes patients
Findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, one of the newer sodium-glucose cotransporter 2 (SGLT2) inhibitors, indicate that the drug does not impact the likelihood of heart attack, stroke, or cardiac death in patients with type 2 diabetes. The findings were presented by a panel of trial investigators, including…